Latest

Understand the 1-mg low-dose dexamethasone suppression test, the common cortisol cutoff of 1.8 mcg/dL, causes of nonsuppression, and the follow-up used for Cushing screening.

Low-Dose Dexamethasone Suppression Test: Cushing Syndrome Screening and Results

Learn how an 8–9 a.m. cortisol test screens for adrenal insufficiency, what low and intermediate results mean, how ACTH helps identify the cause, and when stimulation testing is needed.

Morning Cortisol Test: Low Levels, Adrenal Insufficiency, and Results

Learn how a pheochromocytoma and paraganglioma panel uses plasma or urine metanephrines, normetanephrine, catecholamines, and controlled collection to interpret abnormal results.

Pheochromocytoma and Paraganglioma Test Panel: Metanephrines, Normetanephrine, Catecholamines, and Results

Learn what plasma epinephrine, norepinephrine, and dopamine results mean, why collection posture matters, common causes of high values, and when metanephrine testing is preferred.

Plasma Catecholamines Test: Epinephrine, Norepinephrine, Dopamine, and Results

Learn how plasma free metanephrine and normetanephrine testing screens for pheochromocytoma and paraganglioma, why supine rest matters, and how high or borderline results are evaluated.

Plasma Free Metanephrines Test: Pheochromocytoma and Paraganglioma Screening, High Levels, and Results

Learn what a high plasma normetanephrine result means, why supine rest matters, common false-positive causes, when clonidine testing is used, and how PPGL evaluation proceeds.

Plasma Normetanephrine Test: High Levels, Pheochromocytoma Screening, and Results

Diagnostics

Home Diagnostics Page 3

Understand how a BCHE genetic test, pseudocholinesterase activity, and dibucaine number reveal prolonged succinylcholine or mivacurium paralysis risk and guide safer anesthesia.

BCHE Genetic Test: Pseudocholinesterase Deficiency, Anesthesia Risk, and Results

Understand what CACNA1S genetic test results mean for malignant hyperthermia risk, trigger-free anesthesia, contracture testing, and family screening.

CACNA1S Genetic Test: Malignant Hyperthermia Risk and Results

Learn how DPYD, UGT1A1, TPMT, and NUDT15 results can guide fluoropyrimidine, irinotecan, and thiopurine dosing and toxicity prevention.

Chemotherapy Pharmacogenetic Test: DPYD, UGT1A1, TPMT, and Results

Understand COMT Val158Met results, dopamine metabolism, pain research, medication-response evidence, and why most COMT claims are not clinically actionable.

COMT Genetic Test: Dopamine Metabolism, Pain, Medication Response, and Results

Understand CYP1A2 genetic test results for caffeine and clozapine, including why smoking, inflammation, interactions, and drug levels often matter more.

CYP1A2 Genetic Test: Caffeine, Clozapine, Drug Metabolism, and Results

Understand CYP2B6 test results for efavirenz, methadone, and bupropion, including metabolizer phenotypes, drug-specific guidance, and test limitations.

CYP2B6 Genetic Test: Efavirenz, Methadone, Bupropion, and Results

Learn how CYP2C9 test results affect warfarin, NSAIDs, and phenytoin, including metabolizer types, dose guidance, allele coverage, monitoring, and safety limits.

CYP2C9 Genetic Test: Warfarin, NSAIDs, Phenytoin, and Results

Understand CYP2C19 clopidogrel test results, loss-of-function alleles, Plavix response, alternatives after PCI, and cardiovascular risk implications.

CYP2C19 Clopidogrel Genetic Test: Plavix Response, Heart Risk, and Results

Understand CYP2C19 test results for clopidogrel, antidepressants, and PPIs, including metabolizer types, dosing implications, interactions, and limitations.

CYP2C19 Genetic Test: Clopidogrel, Antidepressants, PPIs, and Results

Understand CYP2D6 and CYP2C19 antidepressant test results, SSRI dosing implications, poor and rapid metabolizer findings, interactions, limits, and follow-up.

CYP2D6 and CYP2C19 Antidepressant Pharmacogenetic Test: SSRI Response and Results

Understand CYP2D6 genetic test results, poor and ultrarapid metabolizer meanings, copy-number issues, drug effects, phenoconversion, and safe clinical use.

CYP2D6 Genetic Test: Drug Metabolism, Poor Metabolizer, and Results

Understand CYP2D6 opioid test results for codeine, tramadol, and oxycodone, including poor and ultrarapid metabolism, interactions, safety, and limits.

CYP2D6 Opioid Pharmacogenetic Test: Codeine, Tramadol, Oxycodone, and Results

Learn what a CYP3A4 genetic test shows, how CYP3A4*22 affects drug metabolism, which medicines may be influenced, and how to interpret results safely.

CYP3A4 Genetic Test: Drug Metabolism, Variants, and Results

Understand CYP3A5 genetic test results, tacrolimus expresser status, genotype-guided starting doses, trough monitoring, and safe transplant medication use.

CYP3A5 Genetic Test: Tacrolimus Dosing, Metabolism, and Results

Learn how DPYD genetic test results, activity scores, and DPD deficiency affect 5-FU and capecitabine dosing, toxicity risk, monitoring, and urgent care.

DPYD Genetic Test: Fluoropyrimidine Toxicity, 5-FU, Capecitabine, and Results

Learn how fluoropyrimidine pharmacogenetic testing uses DPYD results to guide 5-FU and capecitabine starting doses, monitoring, toxicity prevention, and emergency care.

Fluoropyrimidine Pharmacogenetic Test: DPYD, 5-FU, Capecitabine Toxicity, and Results

Understand G6PD genetic testing, enzyme activity, medication hemolysis risk, result interpretation, test limitations, and safe next steps.

G6PD Genetic Test: Medication Hemolysis Risk, Deficiency, and Results

Learn how HLA-A*31:01 testing estimates carbamazepine hypersensitivity risk, how positive and negative results guide prescribing, and which symptoms need urgent care.

HLA-A*31:01 Genetic Test: Carbamazepine Hypersensitivity Risk and Results

Understand HLA-B*15:02 testing for carbamazepine skin reaction risk, result interpretation, ancestry-based screening, related-drug choices, and urgent SJS/TEN warning signs.

HLA-B*15:02 Genetic Test: Carbamazepine Skin Reaction Risk and Results

Understand HLA-B*57:01 testing before abacavir, positive and negative result meaning, hypersensitivity symptoms, permanent rechallenge precautions, and HIV treatment alternatives.

HLA-B*57:01 Genetic Test: Abacavir Hypersensitivity Risk and Results

1 234...57 Page 3 of 57